Further biochemical experiments indicate that the amino acid Thr794 is most likely involved in the molecular interaction between ATP1A3 and CS‐6n and, more importantly, is involved in the chemosensitizing effect of CS‐6 in GBM therapy with TMZ. This evidence concerns the gene ATP1A3 and glioblastoma.